dementia in elderly patients is well recognised, and it can be difficult to separate them into distinct nosological categories (Lauter & Dame, 1991) . Depressed elderly patients often complain of poor memory, and in about 25% the depression is associated with cognitive deficits (Foistein & McHugh, 1978) .Demented patients, mainly in the early stages of the process, tend to complain about depressed mood (Reifler et a!, 1986 ; Forsell et a!, The drug treatment of depression in the elderly is more complicated than in younger patients. Elderly patients suffer more frequently from con comitant diseases and age-related physiological changes, which affect pharmacokinetics and drug The two most important psychiatric illnesses in the elderly are depression and dementia. The estimated prevalence of depression and dementia in the age group over 65 is 10% and 5% respectively (Kay et a!, 1964; Gurland, 1980; Saunders et a!, 1993) Schoerlin & Da Prada, 1990) . The effectiveness and safety ofthis antidepressant hasbeendemonstrated inadultand elderly depressed subjects (Baumhackl et a!, 1989 , Versiani et a!, 1989 Bakish el a!, 1992; Casacchiaeta!,1984 (HAM-D; Hamilton, 1976) were also required for entry into the trial.
Exclusion criteria
Patients with severe uncontrolled systemic diseases (renal, cardiac or pulmonary)or withneurological or other major psychiatric disorders were excluded from the study. Patients with well controlled chronicsomaticdiseases, which are found at high prevalence among depressed and demented pa tients, were admitted. Pretreatment with an in vestigational drug four weeks before the study, the continuousneed for neuroleptics, hypnoticsor anxiolytics in the two weeks prior to the trial, and clinically significant abnormal laboratory tests or ECG were reasons for exclusion.
Permifted medication
The only psychotropic drugs permitted during the trialwere nitrazepam or chloral hydrate as hypnotics, and oxazepam as an anxiolytic up to a maximum dose of 30 mg daily. No restrictions concerningtyramine-containing food were made, but patients were advisedto takethetrial drug at theend of a meal.
Study design
The study was placebo controlled, double-blind, multicentre, withrandom assignment withincentre of patients to either moclobemide or placebofor6 weeks. Treatment was with either a fixed dose of moclobemide 400 mg or a matched placebo. On completionof the trial both groups were offered open treatment with moclobemide for up to 1 year if deemed necessary by the investigator (the results will be communicated elsewhere). A placebo run-in period of 14 days was envisaged but not rigidly enforced. Patients with signs of rapid deterioration during the run-in period were entered into the double-blind treatmentphase, aftera minimum wash-out of four days.
Efficacy parameters
The HAM-D was the main measure of antidepres sant efficacy with assessments at baseline, and after
Method
Male and femalein-and out-patients aged 60 to90 years meeting DSMâ€"III(American Psychiatric Association, 1980) In addition, the Clinical Global Assessment of Efficacy (CGAE) and the Rating Scale for Geriatric Patients (BGP; Kam et a!, 1986) were also used as measures of efficacy. The BGP is a 35-item geriatric rating scale which covers not only psychiatric and cognitive aspects of diseases of the senium but also evaluates the performance of the activities of daily life.
Adverse events
Spontaneous complaints of adverse reactions were recorded at days 10, 21, and 42. The onset and duration of all adverse events were recorded and their severity was rated on a three-point scale (mild, moderate, severe).
Tolerability

A clinical global assessment of tolerability (CGI-T)
on a five point scale (excellent, good, moderate, poor, very poor) was recorded on the 21st and 42nd day after the start of treatment.
Laboratory examinations
Standard laboratory tests and ECG were under taken, and vital functions were measured, at baseline, and at days 21 and 42 of treatment.
Statistics
The safety data are based on the total group of randomised patients. All those who completed 10 days of treatment or gave as a reason for with drawal, lack of efficacy, poor tolerability or adverse effects, were included in the analysis of efficacy as the â€˜¿ intent to treat group' (ITT). The few patients who dropped out for any other reason were excluded from the efficacy analysis but were included in the safety analysis. Within the ITT group analyses were made for those who completed the study (completers) and for those who failed to complete,using theirlastrecordedratings (End Point Analysis). Comparisons between groups were made by t-tests and x2 as appropriate.
Study population
Where patients met DSM-IH criteria for dementia (whether or not they also met DSMâ€"ffl criteria for major depression) they were assigned to the dementia group, as were patients for whom depressive symptoms and cognitive decline were of equal importance, on the principle that organic conditions take diagnostic priority over functional illness. Five hundred and eleven patients fulfilled the DSM-Ill criteria for dementia and were also depressed (DEM + D), 476 of them meeting DSM III criteria for major depressive episode as well; 183 fulfilled the DSMâ€"ffl criteria for major depressive episodes and were also suffering from cognitive decline (MDE + CD), but did not meet DSM-ffl criteria for dementia. Patients with unclassifiable diagnosis (n =14) and patients without efficacy data post-baseline (n = 18) were only included in the safety population. There were no differences in demographic data between centres (Table 1 ). In both diagnostic categories the two treatment groups were well balanced demographically, with no statistically significant difference between them. There were more women than men; most patients were in patients (hospitalised or institutionalised). De pressed patients had a lower mean age (72 years) than the demented patients (74.6 years); 59.6% of moclobemide and 55.4% of placebo treated patients had well controlled concomitant physical diseases of which cardiovascular disease was the most frequent.
Baseline conditions
At the start of the study the two diagnostic groups had comparably high scores on the HAM-D17 Table2 (Fig. 1) , and under placebo by â€"¿ 3.9(DEM + CD) ( Table 2 ). At week 6, significantly more patients treated with moclobemide had a decrease of more than 50% from the baseline recording on the HAM-D17 in the depressed (P<0.00l) and in the demented (P< 0.001) sub-groups. The differences between groups in the End Point Analysis were of the same order of magnitude.
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The change in SCAG scores showed moclobe mide to be superior to placebo in the depressed group and a similar trend, though not statistically significant, was seen in the demented patients. The analysis of the first 4 items of the SCAG (cognitive disturbances, SCAG-I) shows treatment with moclobemide produces significant differences com pared to placebo in the dementia (P = 0.05) and in
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25 - There were no statistically significant differences between treatment groups on the BGP Scale or its subscales.
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Either â€˜¿ marked improvement' or â€˜¿ improvement'
was noted on the CGAE in 51% ofthe depressed and in 59% of the demented patients after placebo treatment, and in 61% (NS v. placebo) of the depressed and in 72% (P<0.00l v. placebo) of the demented patients after moclobemide treatment.
Adverse events
There was no major difference on any safety parameter between the demented and depressed subgroups so they were combined to allow direct comparison between moclobemide and placebo.
The clinical global assessment of tolerability rated at the end of treatment shows similar results for placebo and moclobemide. In 92% of the 358 placebo patients the rating of tolerance was â€˜¿ excellent' or â€˜¿ good' and similarly in 88% of the 368 moclobemide patients (NS). 18.6% of placebo and 14.8% of moclobemide treated patients failed to complete the trial because of lack of efficacy. 41.3% of placebo and 49.2% of moclobemide complained of at least one adverse event in the course of the trial, and there is no statistically significant difference between treatment groups for any adverse event. The most common adverse events are given in Table 3 . In both treatment groups, the most frequent adverse events were nervousness/restlessness, dry mouth, tiredness, headache, agitation, anxiety and sleep disturbances. In the moclobemide group, more dizziness, tiredness and gastrointestinal complaints such as nausea, gastralgia, constipation and diarrhoea were reported, but the differences were small and not statistically significant. 27.4% of adverse events were rated as â€˜¿ severe' in the placebo groups compared with 29% in the moclobemide group. Only eight moclobemide and four placebo patients required the extra psychotropic medication permitted by the proto col. 55.7% of the placebo patients and 48.2% of the moclobemide patients were free of adverse events during the trial period. Where adverse events were experienced they usually occurred in the first nine days of treatment and usually lasted for a few days only, e.g. dizziness: 10.2 days with placebo and 11.8 days with moclobemide, or nausea: moclobemide 2.7 days and placebo 1.6 days. After the first three weeks of treatment, 73% Table 3 Adverse events inthesafetypopulation of the placebo treated patients and 70% of the moclobemide treated patients were free of any adverse event (NS). There was no report of any tyramine reaction. There was no evidence of interactions between moclobemide and the drugs required to control concomitant physical disease. In the course of the trial no significant group differences were detected in body weight, blood pressure, pulse rate or laboratory parameters. showed a response rate of 44% in fluoxetine treated patients compared with a placebo response of 31%; 12% of the fluoxetine and 9% on placebo discontinued because of adverse events. Half of the 16 studies reviewed by Rockwell et a! (1988) had a mean age of 69 or less. Schifano et a! (1990) emphasised the difficulties of diagnosing depression in older people, the frequent presence of additional medical diseases, necessaryadditional treatment (frequently an exclusion criterion in standard trials), and concerns over potentially serious side-effects.
Discussion
Previous trials of antidepressants in the elderly
Moclobemide in the treatment of elderly patients with depressive symptomatology As a reversible inhibitor of MAO-A, moclobemide should have a significant advantage in geriatric populations, due to itslack of anti-cholinergic effects. A large double-blind studyversus imipram me (Baumhackl eta!,1989), which included more than 60 patients aged over 60 years, indicated its efficacy and tolerability. No impairment of cognit ive function was observed in this study or in human pharmacological trials. However, any such advan tages should become even clearer if patients with a pre-existing cognitive deficit are treated; patients suffering from combined depression and cognitive impairment were therefore chosen for this study. That such a population corresponds well to clinical reality is underlined by the difficulty of differentiat ing primary dementia with associated secondary depressive symptoms from true depression, despite the use of various rating scales. In the study described here, 74% met DSMâ€"III criteria for dementia and 26% met the criteria for major depression but not for dementia. If depression is disregarded as a possible cause for dementia and vice versa then 476 of the 511 patients also met DSMâ€"IIIcriteria for major depressive episode.
These cases were classified as demented in the present study because of the hierarchical principle that organic states take priority over functional disorders. Only those patients who did not meet the criteria for dementia but met the criteria for depression were included in the depressed group. Data indicate that this procedure is meaningful. At baseline the HAM-D score was similar in both diagnostic groups, but the patients diagnosed as demented were on average two years older, their impairment of cognition was more intense and they differed also in the spontaneous outcome. Demen ted patients with depression showed a more intense placebo response than patients suffering from major depressive episode with cognitive decline.
On the other hand the placebo response to MMSE and SCAG-I was similar in the two diagnostic sub groups. A fixed dose scheme (400 mg of moclobe mide) was chosen in order to avoid any confound ing effect on the results due to changes in the dosage regime; however, this resulted in a higher rate of premature terminations, due to lack of efficacy some of which could have been avoided by dose changes.
Efficacy
In the analysis of efficacy, the moclobemide group showed a significantly greater mean change from baseline scores on the HAM-D (17 and 24 items), compared withtheplacebogroupinbothdepressed and demented patients. More patients showed a greater than 50% reduction on the HAM-D scale with moclobemide (52% for depressed and 56% for demented) than with placebo (depressed 25%, demented 37%). These figures compare wellwith the results of other antidepressant trials for geriatric depression where the patients were only depressed. Among 24 placebo-controlled studies, only nine showed a higher improvement for the active treatmentthan the median of 52% in the total scoreof the HAM-D (Plotkin et a!,1987) .The clinical global assessment of efficacy indicated an improvementin60% ofthemoclobemidegroup as compared to 48.5% in the placebo group, these differences again being significant. The drop-out rate due to lack of efficacy was also in favour of moclobemide â€"¿ 14.8 v. 18.6%.
The few previous studies looking at old-age patients suffering from major depression with confirmed cognitive deficit showed mean Hamilton improvement of 46% for amitriptyline and mianserin (Branconnier et a!, 1982) and 44% for citalopram (Nyth et a!, 1992) . A mean improve ment of 51% on the HAM-D fits well with these data. The limited response rate in this population group may be partially explained by the symptoms of concomitant physical illness and by the fact that residual symptoms, typical of but not pathogno monic for depression such as late insomnia, loss of weight, gastro-intestinal or other somatic symp toms persist in elderly, previously depressed, patients. On the other hand, it is possible that 6 weeks of treatment is insufficient to achieve the maximum therapeutic effect in elderly depressed patients. Results in a subgroup of patients continued on open moclobemide for 6 months indicate substantial further improvement. The improvement in depression in both depressed and demented groups shows the importance of treating depression even though the depressed patient also has a diagnosis of dementia.
During the double-blind phase the amelioration of the Hamilton score was parallel with that of the SCAG factor I and the MMSE, indicating an amelioration of the cognitive function rather than a practice effect. Although there was improvement in cognitive function in the demented group, this study does not allow us to decide if moclobemide relieved only the cognitive disturbances secondary to depression or if it has a mood independent effect on cognitive disturbance. A further trial in cognitively impaired patients without depression is required to answer this question.
Tolerability
The Clinical Global Assessment of tolerance indicated excellent or good tolerance in 88% of the moclobemide group and 92% of the placebo group. With the exception of dizziness and nausea, which approached statistical difference favouring placebo (0.1 >P>0.05), the total frequency of adverse events was approximately equal in both groups, as well as the distribution of events rated as â€˜¿ severe'. The number of patients with any adverse events was slightly, but not significantly higher with moclobemide than with placebo. A slightly higher proportion of premature terminations due to adverse events with moclobemide (8.4% v. 4.7%), and though not significant, has to be seen in the context of a fixed dose scheme, which permitted no adaptation in case of an individual higher sensitivity to adverseevents. In general, therefore, moclobe mide was not very different from placebo in terms of tolerance and the frequency of adverse events, in this elderly population. It is noteworthy that side-effects occurred more frequently in the first nine days in both treated groups and were shortlived. It should be borne in mind that the fixed dose scheme did not allow any adaptation in cases of insufficient efficacy or poor tolerance and that the inclusion of patients with concomitant physical illness and additional cognitive deficits or primary dementia and secondary depression led to a substantially more ill population being treated, than in some other studies. It is highly likely that these factors and the high mean age of the sample (73.6) contributed to a lower response rate in this trial compared to studies in younger populations, although the superiority of moclobemide over placebo remains clearly significant.
Conclusions
This study represents the largest double-blind placebo-controlled study which has been conducted in an elderly depressed population suffering ad ditionally from cognitive impairment. There was a slight positive effect of moclobemide on the cognitive deficits in this sample of patients, but it is possible that this was secondary to the drug's antidepressant and drive-enhancing effects. On the other hand, it is clear that cognitive function is not impaired by moclobemide in these older patients, though this may be a troublesome effect with most of the TCAs, because of their anticholinergic and sedating action. The results of this study demon strate a good safety and efficacy profile for moclobemide 2 x 200 mg/day in the elderly. There was no evidence of cognitive impairment as a result of treatment with moclobemide in this study. 
